nach oben

International Journal of Hematology

Erschienen in:

22.08.2019 | Original Article

Comprehensive prognostic scoring systems could improve the prognosis of adult acute myeloid leukemia patients

verfasst von: Fan Zhou, Fen Zhou, Mengyi Du, Lin Liu, Tao Guo, Linghui Xia, Runming Jin, Yu Hu, Heng Mei

Erschienen in: International Journal of Hematology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Acute myeloid leukemia (AML) is a heterogeneous malignancy characterized by a dismal outcome. To enable better outcomes, it is necessary to develop individual therapies based on risk stratification. In the present study, we established two new comprehensive prognostic scoring systems (CPSS) for overall survival (OS) and relapse-free survival (RFS) using the Cox proportional hazards regression, CPSS integrated and weighted age, AML type, lactic dehydrogenase (LDH), ECOG score, cytogenetics, and gene mutations. We divided patients into three risk groups—low-, intermediate-, and high-risk—with 1-year OS rates of 100.0%, 82.9%, and 38.2%, respectively (p < 0.0001), and patients undergoing complete remission (CR) were also separated into low-risk, intermediate-risk, and high-risk groups, with 1-year RFS rates of 87.7%, 58.4%, and 30.2%, respectively (p < 0.0001). We conclude that CPSS that integrate clinical characteristics, cytogenetic abnormalities, and gene mutations may improve the stratification of AML patients.

Nur mit Berechtigung zugänglich

Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392(10147):593–606.CrossRefPubMed

Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373(12):1136–52.CrossRefPubMed

Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–89.CrossRefPubMed

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–406.CrossRefPubMed

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47.CrossRefPubMedPubMedCentral

O’Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, et al. Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15(7):926–57.CrossRef

Patel U, Luthra R, Medeiros LJ, Patel KP. Diagnostic, prognostic, and predictive utility of recurrent somatic mutations in myeloid neoplasms. Clin Lymphoma Myeloma Leuk. 2017;17(July):S62–74.CrossRef

Larsson CA, Cote G, Quintás-Cardama A. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome. Mol Cancer Res. 2013;11(8):815–27.CrossRefPubMedPubMedCentral

Rafael B. Splicing factor mutations in cancer. In: Yeo GW, editor. RNA processing, vol. 907. Switzerland: Springer; 2016. p. 215–28.CrossRef

10.

Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–21.CrossRefPubMedPubMedCentral

11.

Ahn J-S, Kim H-J, Kim Y-K, Lee S-S, Ahn S-Y, Jung S-H, et al. Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype. Oncotarget. 2017;9(4):4961–8.PubMedPubMedCentral

12.

Djunic I, Suvajdzic-Vukovic N, Virijevic M, Novkovic A, Colovic N, Vidovic A, et al. Prognostic risk score for the survival of elderly patients with acute myeloid leukaemia comprising comorbidities. Med Oncol. 2013;30(1):394.CrossRefPubMed

13.

Wheatley K, Brookes CL, Howman AJ, Goldstone AH, Milligan DW, Prentice AG, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol. 2009;145(5):598–605.CrossRefPubMed

14.

Malfuson JV, Etienne A, Turlure P, de Revel T, Thomas X, Contentin N, et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica. 2008;93(12):1806–13.CrossRefPubMed

15.

Wiese M, Daver N. Unmet clinical needs and economic burden of disease in the treatment landscape of acute myeloid leukemia. Am J Manag Care. 2018;24(16 Suppl):S347–55.PubMed

16.

Bullinger L, Döhner K, Döhner H. Genomics of acute myeloid leukemia diagnosis and pathways. J Clin Oncol. 2017;35(9):934–46.CrossRefPubMed

17.

Østgård LSG, Medeiros BC, Sengeløv H, Nørgaard M, Andersen MK, Dufva IH, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33(31):3641–9.CrossRef

18.

Kuykendall A, Duployez N, Boissel N, Lancet JE, Welch JS. Acute myeloid leukemia: the good, the bad, and the ugly. Am Soc Clin Oncol Educ B. 2018;23(38):555–73.CrossRef

19.

Teng CL, Young JH, Hsu SL, Chou G, Kuo IT, Yu CY, et al. Lactate dehydrogenase, not vascular endothelial growth factor or basic fibroblast growth factor, positively correlates to bone marrow vascularity in acute myeloid leukemia. J Chin Med Assoc. 2006;69(11):534–7.CrossRefPubMed

20.

Röllig C, Thiede C, Gramatzki M, Aulitzky W, Bodenstein H, Bornhäuser M, et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood. 2010;116(6):971–8.CrossRefPubMed

21.

Basiricò R, Pirrotta R, Fabbiano F, Mirto S, Cascio L, Pagano M, et al. Submicroscopic deletions at 7q region are associated with recurrent chromosome abnormalities in acute leukemia. Haematologica. 2003;88(4):429–37.PubMed

22.

Breems DA, Van Putten WL, De Greef GE, Van Zelderen-Bhola SL, Gerssen-Schoorl KB, Mellink CH, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29):4791–7.CrossRefPubMed

23.

Nazha A, Kantarjian HM, Bhatt VR, Nogueras-Gonzalez G, Cortes JE, Kadia T, et al. Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics. Clin Lymphoma Myeloma Leuk. 2014;14(2):163–71.CrossRefPubMedPubMedCentral

24.

Poiré X, Labopin M, Maertens J, Yakoub-Agha I, Blaise D, Ifrah N, et al. Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2018;103(2):256–65.CrossRefPubMedPubMedCentral

25.

Pastore F, Dufour A, Benthaus T, Metzeler KH, Maharry KS, Schneider S, et al. Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2014;32(15):1586–94.CrossRefPubMedPubMedCentral

26.

Malagola M, Skert C, Vignetti M, Piciocchi A, Martinellli G, Alimena G, et al. A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. Leuk Lymphoma. 2011;52(12):2329–35.CrossRefPubMed

27.

Lin P-H, Li H-Y, Fan S-C, Yuan TH, Chen M, Hsu Y-H, et al. A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice. Cancer Med. 2017;6(2):349–60.CrossRefPubMedPubMedCentral

28.

Stölzel F, Pfirrmann M, Aulitzky WE, Kaufman M, Bodenstein H, Bornhäuser M, et al. Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial. Leukemia. 2011;25(3):420–8.CrossRefPubMed

29.

Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378(13):1189–99.CrossRefPubMed

30.

Hoskins AA, Moore MJ. The spliceosome: a flexible, reversible macromolecular machine. Trends Biochem Sci. 2012;37(5):179–88.CrossRefPubMedPubMedCentral

31.

Zhou J, Chng WJ. Aberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukemia. Stem Cell Investig. 2017;4:6.CrossRefPubMedPubMedCentral

32.

Yohe S. Molecular genetic markers in acute myeloid leukemia. J Clin Med. 2015;4(3):460–78.CrossRefPubMedPubMedCentral

33.

Ayatollahi H, Shajiei A, Sadeghian MH, Sheikhi M, Yazdandoust E, Ghazanfarpour M, et al. Prognostic importance of C-KIT mutations in core binding factor acute myeloid leukemia: a systematic review. Hematol Oncol Stem Cell Ther. 2017;10(1):1–7.CrossRefPubMed

34.

Chen W, Xie H, Wang H, Chen L, Sun Y, Chen Z, et al. Prognostic significance of KIT mutations in core-binding factor acute myeloid leukemia: a systematic review and meta-analysis. PLoS One. 2016;11(1):1–19.

35.

Manara E, Bisio V, Masetti R, Beqiri V, Rondelli R, Menna G, et al. Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations. Leukemia. 2014;28(5):1132–4.CrossRefPubMed

36.

Krauth MT, Eder C, Alpermann T, Bacher U, Nadarajah N, Kern W, et al. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome. Leukemia. 2014;28(7):1449–58.CrossRefPubMed

37.

Qin Y-Z, Zhu H-H, Jiang Q, Xu L-P, Jiang H, Wang Y, et al. Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21). Blood Cancer J. 2018;8(8):76.CrossRefPubMedPubMedCentral

Titel: Comprehensive prognostic scoring systems could improve the prognosis of adult acute myeloid leukemia patients
verfasst von: Fan Zhou
Fen Zhou
Mengyi Du
Lin Liu
Tao Guo
Linghui Xia
Runming Jin
Yu Hu
Heng Mei
Publikationsdatum: 22.08.2019
Verlag: Springer Japan
Erschienen in: International Journal of Hematology / Ausgabe 5/2019
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-019-02721-y

Neu im Fachgebiet Onkologie

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Springer Medizin

Comprehensive prognostic scoring systems could improve the prognosis of adult acute myeloid leukemia patients

Abstract

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Osteosclerotic myeloma without features of POEMS syndrome

A less-intensive anticoagulation protocol of therapeutic unfractionated heparin administration for pregnant patients

Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients

Discrepancy in the degree of polycythemia in a family with a novel nonsense EPOR mutation

Essential thrombocytosis attributed to JAK2-T875N germline mutation

Bortezomib-containing therapy in Japanese children with relapsed acute lymphoblastic leukemia

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie